Edwards Shares Superior Long-Term Outcomes from TAVR Studies
Edwards Lifesciences announced new data demonstrating long-term benefits with its Sapien heart valve system.
Seven-year data from the PARTNER 3 trial showed early and sustained patient benefits of Edwards’ transcatheter aortic valve replacement (TAVR) system.
- Superior clinical outcomes at one year
- Strong long-term valve performance and durability
Additionally, 10-year results from PARTNER 2 intermediate risk studies reinforced the company’s valve’s lasting performance and outcomes across all risk profiles and generations.
These findings were shared at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
Edwards shared new long-term findings for the Evoque and Sapien M3 valves.
Author summary: Edwards Lifesciences shares long-term benefits of its Sapien heart valve system.
More News
- Resident doctor industrial action in England: National webinar
- Live updates: Early Yukon election results show some tight races, some comfortable leads for Yukon Party incumbent MLAs
- Could Melatonin Be Silently Harming Your Heart?
- Live updates: Poll results begin to arrive in 2025 Yukon elections
- Live updates: Early Yukon election results show some tight races, some comfortable leads for Yukon Party incumbent MLAs
- On 'Lux,' Rosalía pulls the entire world into her symphony